See the DrugPatentWatch profile for Alprolix
The annual cost of Alprolix (emapizumab-lvg) can vary significantly depending on several factors, including dosage, treatment frequency, and insurance coverage. However, it is a high-cost medication. For example, a single infusion of Alprolix can range from approximately $10,000 to over $20,000. Given that many patients require regular infusions, the yearly expenditure can reach hundreds of thousands of dollars.
What is Alprolix used to treat?
Alprolix is a factor IX and factor Xa bypassing agent indicated for adults and children with hemophilia B. It is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes [1].
How does Alprolix work?
Alprolix is a recombinant human coagulation factor IX, an essential protein in the blood clotting cascade. It is engineered to remain in the bloodstream longer than naturally occurring factor IX, providing sustained protection against bleeding [1].
What is the typical dosage and administration of Alprolix?
The recommended dose and frequency of Alprolix are based on individual patient weight, pharmacokinetic (PK) assessments, and the desired trough factor IX level. For routine prophylaxis, it is typically administered once every 7 days, or once every 10 days, depending on the patient's needs and PK profile [1].
When does Alprolix's patent protection expire?
The patent landscape for Alprolix is complex. The drug's originator is Takeda Pharmaceutical Company. Patent expiry dates can be influenced by various factors, including regulatory exclusivities and new patent filings. Information on specific patent expiry timelines can be found through resources like DrugPatentWatch.com [2].
What are the potential side effects of Alprolix?
The most common side effects reported in clinical trials for Alprolix include headache, nasopharyngitis, pyrexia, and injection site reactions. Serious adverse reactions, such as hypersensitivity reactions, have also been reported [1].
How does Alprolix compare to other hemophilia B treatments?
Alprolix offers extended half-life prophylaxis, meaning patients may require less frequent infusions compared to older, shorter-acting factor IX products. Other treatment options for hemophilia B include conventional factor IX concentrate infusions and gene therapy approaches [1]. The choice of treatment depends on individual patient factors, physician recommendations, and the availability of different therapies.
Are there financial assistance programs for Alprolix?
Given the high cost of Alprolix, patients may be eligible for financial assistance programs offered by the manufacturer or through patient advocacy groups. These programs can help offset out-of-pocket expenses and make the treatment more accessible [3].
*
**Sources:
1. https://www.alprolix.com/
2. https://drugpatentwatch.com/
3. https://www.takeda.com/patients/